These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27628239)

  • 41. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.
    Esteves AR; Gozes I; Cardoso SM
    Biochim Biophys Acta; 2014 Jan; 1842(1):7-21. PubMed ID: 24120997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Binding of neuronal α-synuclein to β-III tubulin and accumulation in a model of multiple system atrophy.
    Nakayama K; Suzuki Y; Yazawa I
    Biochem Biophys Res Commun; 2012 Jan; 417(4):1170-5. PubMed ID: 22227187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Α-synuclein misfolding and Parkinson's disease.
    Breydo L; Wu JW; Uversky VN
    Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Fundamental mechanisms of amyloid fibril formation by alpha-synuclein in Parkinson's disease: quantitative modelling].
    Galvagnion C; Buell AK
    Med Sci (Paris); 2015; 31(6-7):597-600. PubMed ID: 26152159
    [No Abstract]   [Full Text] [Related]  

  • 45. High pressure promotes alpha-synuclein aggregation in cultured neuronal cells.
    Golebiewska U; Scarlata S
    FEBS Lett; 2015 Oct; 589(21):3309-12. PubMed ID: 26434717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein.
    Galvagnion C; Brown JW; Ouberai MM; Flagmeier P; Vendruscolo M; Buell AK; Sparr E; Dobson CM
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7065-70. PubMed ID: 27298346
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease.
    Bellucci A; Zaltieri M; Navarria L; Grigoletto J; Missale C; Spano P
    Brain Res; 2012 Oct; 1476():183-202. PubMed ID: 22560500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
    Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
    PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha-synuclein aggresomes inhibit ciliogenesis and multiple functions of the centrosome.
    Iqbal A; Baldrighi M; Murdoch JN; Fleming A; Wilkinson CJ
    Biol Open; 2020 Oct; 9(10):. PubMed ID: 32878882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ca2+ is a key factor in α-synuclein-induced neurotoxicity.
    Angelova PR; Ludtmann MH; Horrocks MH; Negoda A; Cremades N; Klenerman D; Dobson CM; Wood NW; Pavlov EV; Gandhi S; Abramov AY
    J Cell Sci; 2016 May; 129(9):1792-801. PubMed ID: 26989132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of N-terminal Acetylation on the Aggregation of Disease-related α-synuclein Variants.
    Bell R; Castellana-Cruz M; Nene A; Thrush RJ; Xu CK; Kumita JR; Vendruscolo M
    J Mol Biol; 2023 Jan; 435(1):167825. PubMed ID: 36099961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The remarkable conformational plasticity of alpha-synuclein: blessing or curse?
    Deleersnijder A; Gerard M; Debyser Z; Baekelandt V
    Trends Mol Med; 2013 Jun; 19(6):368-77. PubMed ID: 23648364
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formation and Characterization of α-Synuclein Oligomers.
    Paslawski W; Lorenzen N; Otzen DE
    Methods Mol Biol; 2016; 1345():133-50. PubMed ID: 26453210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.
    Bobela W; Aebischer P; Schneider BL
    Biomolecules; 2015 Oct; 5(4):2675-700. PubMed ID: 26501339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. β-Synuclein suppresses both the initiation and amplification steps of α-synuclein aggregation via competitive binding to surfaces.
    Brown JW; Buell AK; Michaels TC; Meisl G; Carozza J; Flagmeier P; Vendruscolo M; Knowles TP; Dobson CM; Galvagnion C
    Sci Rep; 2016 Nov; 6():36010. PubMed ID: 27808107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The behavior of alpha-synuclein in neurons.
    Fortin DL; Nemani VM; Nakamura K; Edwards RH
    Mov Disord; 2010; 25 Suppl 1():S21-6. PubMed ID: 20187244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins.
    Schnack C; Danzer KM; Hengerer B; Gillardon F
    Neuroscience; 2008 Jul; 154(4):1450-7. PubMed ID: 18541383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.